Insulet (PODD) has come under closer scrutiny after initiating multiple Class I recalls of its Omnipod insulin delivery devices, followed by securities class action filings that question the company’s disclosures around manufacturing controls and product safety.

After the Class I recalls and class action announcements, Insulet’s share price has been volatile, with a 12.55% 1 month share price return but a year to date share price return down 42.01%. The 1 year total shareholder return has also declined 42.28%, indicating pressure on sentiment despite product launches like Omnipod 5 in Spain and the Calm partnership.

If you are weighing how this kind of product and regulatory risk shows up in other areas of the market, it can help to contrast Insulet with companies exposed to AI driven healthcare tools by scanning the 39 healthcare AI stocks.

Insulet still runs a sizeable, growing insulin delivery business, yet the recalls and class actions have reset expectations and sentiment. After a sharp share price reset, is this a strong company that is now priced attractively, or not?

Most Popular Narrative: 32.3% Undervalued

Insulet’s most followed valuation narrative points to a fair value of $242.43 per share versus the last close at $164.06, framing the current recall driven uncertainty against a higher long run cash flow outlook.

Rapidly rising adoption of Omnipod 5 in both the U.S. and international markets, driven by strong clinical evidence, ease of use, and superior integration with the latest glucose sensors, is positioning Insulet to capture a disproportionately large share of the expanding global diabetes device market, supporting outsized top-line revenue growth for several years.

Curious how that projected growth translates into today’s $242.43 fair value estimate for Insulet? The narrative hinges on compounding revenue, rising margins, and a future earnings multiple that assumes the market keeps rewarding Omnipod’s expansion path without paying current P/E levels forever.

Result: Fair Value of $242.43 (UNDERVALUED)

However, this Insulet narrative still hinges on Omnipod concentration and ongoing regulatory and quality control scrutiny. Any slip in either could quickly challenge today’s valuation case.

Another View: Insulet Through a P/E Lens

The SWS DCF model suggests Insulet is trading at a discount to its estimated future cash flow value of $367.71 per share, yet the current P/E of 37.5x is higher than the US Medical Equipment industry at 27.2x, the peer average at 35.3x, and the fair ratio of 32.1x. That gap implies you may be paying a richer price today for growth that models already build in. How comfortable are you with that trade off?

Next Steps

With such a mixed picture around Insulet’s recalls, growth narratives, and valuation, do not wait for consensus to form. Instead, check the details yourself and weigh both sides of the story against your own risk tolerance with the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Insulet?

If Insulet has sharpened your focus on risk, growth and valuation, do not stop here. Broaden your watchlist with fresh ideas that match your style.

• Target stability first by reviewing companies highlighted in the 83 resilient stocks with low risk scores so your portfolio is not leaning only on higher risk stories.
• Hunt for strong balance sheets by scanning the solid balance sheet and fundamentals stocks screener (47 results) and find businesses that back their potential with financial strength.
• Spot potential standouts early by checking the screener containing 20 high quality undiscovered gems before others start paying attention to them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.